［1］Cabanillas ME，McFadden DG，Durante C，et al.Thyroid cancer［J］.Lancet，2016，388(10061)：2783-2795.
[2]Zahra Nozhat，Mehdi Hedayati，Feridoun Azizi，et al.Thyroid cancer epidemic：A peril or an alarm［J］? Int J Endocrinol Metab，2015，13(4)：e28491- e28492.
[3]Nachalon Y，Hilly O，Segal K，et al.Radiation-induced well-differentiated thyroid cancer：Disease characteristics and survival［J］.Isr Med Assoc J，2016，18(2)：90-94.
[4]Kim KB，Cabanillas ME，Lazar AJ，et al.Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF V600E mutation［J］.Thyroid，2013，23(10)：1277-1283.
[5]Dadu R，Shah K，Busaidy NL，et al.Efficacy and tolerability of vemurafenib in patients with BRAF V600E-positive papillary thyroid cancer：M.D.Anderson Cancer Center off label experience［J］.J Clin Endocrinol Metab，2015；100(1)：E77-81.
[6]Li P，Gu T，Wang C，et al.Neuregulin 1 attenuates neuronal apoptosis induced by deep hypothermic circulatory arrest through ErbB4 signaling in rats［J］.J Cardiovasc Pharmacol，2015，66(6)：551-557.
[7]Kotzadimitriou D，Nissen W，Paizs M，et al.Neuregulin 1 type I overexpression is associated with reduced NMDA receptor-mediated synaptic signaling in hippocampal interneurons expressing PV or CCK［J］.eNeuro，2018，5(2):418-436.
[8]Guo Y，Duan Z，Jia Y，et al.HER4 isoform CYT2 and its ligand NRG1III are expressed at high levels in human colorectal cancer［J］.Oncol Lett，2018，15(5)：6629-6635.
[9]Trombetta D，Graziano P，Scarpa A，et al.Frequent NRG1 fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression［J］.Oncotarget，2018，9(11)：9661-9671.
[10]Ocana A，Diez-Gonzalez L，Esparis-Ogando A，et al.Neuregulin expression in solid tumors：Prognostic value and predictive role to anti-HER3 therapies［J］.Oncotarget，2016，7(29)：45042-45051.
[11]Olaya JC，Heusner CL，Matsumoto M，et al.Schizophrenia-relevant behaviours of female mice overexpressing neuregulin 1 type III［J］.Behav Brain Res，2018，353:227-235.
[12]Korkaya H，Paulson A，Iovino F，et al.HER 2 regulate the mammary stem/progenitor cell population driven tumorigenesis invasion［J］.Oncogene，2008，27(47)：6120-6130.
[13]Yip L，Sosa JA.Molecular-directed treatment of differentiated thyroid cancer：Advances in diagnosis and treatment［J］.JAMA Surg，2016，151(7)：663-670.
[14]Chua YL，Ito Y，Pole JC，et al.The NRG1 gene is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor gene［J］ .Oncogene，1998，17(16)：2107-2113.
[15]Weinstein EJ，Grimm S，Leder P.The oncogene heregulin induces apoptosis in breast epithelial cells and tumors［J］.Oncogene，2009，28(46)：4041-4052.
[16]Flanagan L，Meyer M，Fay J，et al.Low levels of Caspase-3 predict favourable response to 5FU-based chemotherapy in advanced colorectal cancer：Caspase-3 inhibition as a therapeutic approach［J］.Cell Death Dis，2016，7(2)：2087-2098.
[17]Opferman JT，Kothari A.Anti-apoptotic BCL-2 family members in development［J］.Cell Death Differ，2018，25(1)：37-45.
[18]Schwarz LJ，Hutchinson KE，Rexer BN，et al.An ERBB1-3 neutralizing antibody mixture with high activity against drug-resistant HER2+breast cancers with ERBB ligand overexpression［J］ .J Natl Cancer Inst，2017，109(11)：1093-1105.
[19]Le XF，Marcelli M，McWatters A，et al.Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C alpha activity［J］.Oncogene，2001，20(57)：8258-8269.